CDMO News
Ratio Therapeutics Partners with CDMO Macrocyclics to Expand Access to Macropa
Ratio Therapeutics Inc. has entered into an exclusive agreement with Macrocyclics Inc., granting the CDMO the global manufacturing and distribution rights to its proprietary Actinium-225 chelator, Macropa™. The deal aims to expand worldwide access to the bifunctional chelator, enabling researchers across industry
16 June 2025